Department of Clinical Neurosciences, Cumming School of Medicine, Neurologic Clinic and Policlinic, MS, University of Calgary, Calgary, Alberta, Canada; Hotchkiss Brain Institute, Cumming School of Medicine, Neurologic Clinic and Policlinic, MS, University of Calgary, Calgary, Alberta, Canada.
Department of Clinical Neurosciences, Cumming School of Medicine, Neurologic Clinic and Policlinic, MS, University of Calgary, Calgary, Alberta, Canada; Hotchkiss Brain Institute, Cumming School of Medicine, Neurologic Clinic and Policlinic, MS, University of Calgary, Calgary, Alberta, Canada; University Hospital and School of Medicine, UANL, Monterrey, Mexico.
J Neuroimmunol. 2022 Mar 15;364:577803. doi: 10.1016/j.jneuroim.2021.577803. Epub 2021 Dec 30.
There are no reliable biomarkers that predict disability worsening in progressive Multiple Sclerosis (MS). We analyzed circulating biomarkers of hypoxia and angiogenesis in people with Secondary Progressive MS (SPMS) who participated in a clinical trial and were monitored prospectively for disability worsening. Concentrations of glucose transporter-1 (Glut-1), a marker of hypoxia, were higher in SPMS compared to controls. Moreover, low levels of angiopoietin-2 (APN2) and hepatocyte growth factor (HGF) were associated with disability worsening, while neurofilament light, an emerging biomarker in MS, was not. APN2 and HGF are neurotrophic and could be both potential biomarkers and therapeutic targets in SPMS.
目前尚无可靠的生物标志物可预测多发性硬化症（MS）的残疾进展。我们分析了参与临床试验并前瞻性监测残疾进展的继发性进展型多发性硬化症（SPMS）患者的缺氧和血管生成的循环生物标志物。葡萄糖转运蛋白-1（Glut-1）的浓度在 SPMS 患者中高于对照组，Glut-1 是缺氧的标志物。此外，血管生成素-2（APN2）和肝细胞生长因子（HGF）水平较低与残疾进展相关，而神经丝轻链，一种 MS 的新兴生物标志物，与残疾进展无关。APN2 和 HGF 具有神经营养作用，可能都是 SPMS 的潜在生物标志物和治疗靶点。
